Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Moreover, the genotype of patients in the PsA cohort was shown to be heterogeneous with significant elevations in the frequency of haplotypes containing HLA-B*08, HLA-C*06:02, HLA-B*27, HLA-B*38 and HLA-B*39.
|
25948071 |
2015 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.
|
30552173 |
2019 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis.
|
31074583 |
2019 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This large case-control and family based association study shows that HLA-C*12/B*38, HLA-B*27 and HLA-C*06/B*57 are haplotypes (alleles) robustly associated with PsA.
|
23916976 |
2013 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.
|
26626624 |
2015 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Certain HLA-B and HLA-C alleles confer susceptibility to PsA among patients with psoriasis and may be used to identify patients with PsC who may develop PsA.
|
21900282 |
2012 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To explore the potential genotypic effects of pairwise combinations of different HLA-B and C alleles/haplotypes, we created a series of allele/haplotype risk scores combining single alleles/haplotypes separately associated with being in the highest PsA severity propensity tertile based on the features studied by univariate analysis.
|
25261574 |
2016 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Allele frequencies were calculated and logistic regressions were performed, adjusting for HLA-B and HLA-C alleles previously shown to be associated with psoriasis and/or PsA.
|
21457151 |
2011 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
After controlling for the age of psoriasis onset no association of PsA to HLA-C*06:02 (p=0.07) was observed; instead, the most significant association was to amino acid at position 97 of HLA-B (p=1.54×10<sup>-9</sup>) where the presence of asparagine or serine residue increased PsA risk.
|
28821532 |
2017 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A variety of clinical indices exist to assess enthesitis in PsA; however, the Leeds Enthesitis Index and Maastricht Ankylosing Spondylitis Enthesitis Score index have been the most frequently used indices in recent clinical trials.
|
29429762 |
2018 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Obesity is linked with late-onset psoriasis and PsA, while normal weight is associated with the presence of the HLA-B*27 allele and an earlier onset of the disease.
|
28202737 |
2017 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Regression analysis demonstrated a significant association of SI with peripheral joint erosions (p=0.043), PASI maximum (p=0.041), younger age of PsA onset (p=<0.001), presence of HLA-B*0801 (p=0.002) and only marginal significance with HLA-B*2705 (p=0.059).
|
27974100 |
2017 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
In contrast, HLA-B*58 was more common in controls than in PsA and psoriasis groups, and the prevalence of HLA-DR*17 was significantly higher in controls than in those with psoriasis.
|
18381784 |
2008 |
Arthritis, Psoriatic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The relationship between disease activity or clinical response during the first 12 weeks of treatment and achievement of week-48 targets (for axial SpA: inactive disease based on Ankylosing Spondylitis Disease Activity Score [ASDAS] using the C-reactive protein [CRP] level, or Bath Ankylosing Spondylitis Disease Activity Index <2 with normal CRP level; and for PsA: minimal disease activity) was assessed post hoc using RAPID-axSpA and RAPID-PsA trial data.
|
27696727 |
2017 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Clearly, PsV and PsA are highly variable in terms of their clinical manifestations, and this heterogeneity can partially be explained by differences in HLA-associations (HLA-Cw*0602 versus HLA-B*27, for example).
|
26780035 |
2016 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
The MICA-129 methionine (Met) allele, particularly Met/Met homozygosity, was strongly associated with both cutaneous psoriasis (PsC) and psoriatic arthritis (PsA) independently of HLA-B and HLA-C in Toronto patients, and was also associated with PsA in St. John's patients, but with no additional effect of Met/Met homozygosity.
|
23611695 |
2013 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Impact of Comorbidity on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results from the CARdiovascular in rheuMAtology (CARMA) study.
|
31033231 |
2019 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
GWASDB |
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.
|
20953186 |
2010 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Flare was defined as change in 28 Joint Disease Activity Score (∆DAS28) ≥1.2 (RA/PsA) or Ankylosing Spondylitis Disease Activity Score (∆ASDAS) ≥1.3 (AxSpA).
|
28473425 |
2017 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
The following information was recorded in web-based case report forms: demographic, clinical and radiographic data; physical examination findings, including tender and swollen joint counts (TJC and SJC); nail and skin involvement; Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS 28-ESR); Bath Ankylosing Spondylitis Disease Activity Index (BASDAI); Maastricht Ankylosing Spondylitis Enthesitis Score (MASES); Psoriasis Area Severity Index (PASI); Bath Ankylosing Spondylitis Radiology Index for the spine (BASRI-s); Health Assessment Questionnaire (HAQ); Bath Ankylosing Spondylitis Functional Index (BASFI); Health Assessment Questionnaire for the spondyloarthropathies (HAQ-s); Psoriatic arthritis quality of Life scale (PsAQoL); Short Form 36 (SF-36); Hospital Anxiety Depression Scale (HADS); Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F); and Fibromyalgia Rapid Screening Tool (FiRST) scores.
|
31773391 |
2020 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
LHGDN |
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies.
|
16200572 |
2005 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The human leukocyte antigen-C0602 allele confers the highest risk for psoriasis whereas several human leukocyte antigen-B alleles were identified as 'PsA-specific' genes.
|
25415529 |
2015 |
Arthritis, Psoriatic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
|
31203228 |
2019 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Some findings can be concluded from the study: (1) the frequency of HLA-B*5701, B*3801, B*39, B*27, Cw*0602, Cw*07, DRB1*0402, and DRB1*0701 were not found to be significantly increased in PsA; (2) no significant differences of TNFalpha promoter alleles at positions -308 and -238 were found between PsA and healthy controls; (3) the trinucleotide repeat polymorphism MICA-A9 was present at a higher frequency in PsA patients, (p(c) < 0.009, RR = 3.34, EF = 0.39); and (4) MICA-A9 polymorphism was found in linkage disequilibrium with HLA-B alleles (B*5701, B*3801) described to be associated with PsA in Caucasians.
|
11390038 |
2001 |
Arthritis, Psoriatic
|
0.200 |
GeneticVariation
|
disease |
LHGDN |
Comparing PsA and psoriasis, the prevalence of HLA-B*27 and HLA-Cw*12 were more common in PsA patients, while the prevalence of HLA-DR*07 was higher in those with psoriasis (p < 0.05).
|
18381784 |
2008 |